News articles about Icon Plc (NASDAQ:ICLR) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Icon Plc earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 43.0447108787201 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Shares of Icon Plc (NASDAQ:ICLR) opened at 101.40 on Friday. Icon Plc has a one year low of $73.76 and a one year high of $109.32. The company has a 50-day moving average of $100.50 and a 200 day moving average of $89.05. The firm has a market cap of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60.

Icon Plc (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.30 by $0.01. The firm had revenue of $431 million for the quarter, compared to analyst estimates of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. Icon Plc’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. On average, equities research analysts expect that Icon Plc will post $5.32 EPS for the current fiscal year.

ICLR has been the topic of several research reports. Jefferies Group LLC raised shares of Icon Plc from a “hold” rating to a “buy” rating and increased their price target for the stock from $86.00 to $117.00 in a research report on Thursday, June 29th. Zacks Investment Research raised shares of Icon Plc from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Tuesday, June 27th. BidaskClub raised shares of Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a research report on Friday, July 28th. Finally, SunTrust Banks, Inc. raised shares of Icon Plc from a “hold” rating to a “buy” rating and increased their price target for the stock from $93.00 to $126.00 in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Icon Plc has an average rating of “Buy” and an average target price of $108.38.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Icon Plc (NASDAQ:ICLR) Share Price” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-icon-plc-nasdaqiclr-share-price.html.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Insider Buying and Selling by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.